Advertisement
Solvay
Subscribe to Solvay

The Lead

Abbott 3Q Profit Falls on Solvay, Meridia Costs

October 20, 2010 4:50 am | News | Comments

NEW YORK (AP) — Abbott Laboratories said today its third-quarter net income dropped 40 percent on costs connected with its purchase of Belgian drugmaker Solvay Pharmaceuticals and its recall of the diabetes drug Meridia.

Eurand Names Former Solvay Executive Jean-Louis Anspach President of U.S. Pharmaceuticals Business

June 16, 2010 4:49 am | News | Comments

Eurand N.V., a global specialty pharmaceutical company, today announced the appointment of Jean-...

Abbott Gets European Clearance for Solvay Deal

February 12, 2010 8:49 am | News | Comments

NEW YORK (AP) — European regulators gave Abbott Laboratories antitrust clearance to buy Solvay's...

Solvay Sells Pharma Division to Abbott for $7.6B

September 28, 2009 4:33 am | News | Comments

BRUSSELS (AP) — Solvay, the Belgian chemical and pharmaceutical group, said Monday it has agreed to...

View Sample

FREE Email Newsletter

Study: Diabetes Drug Lowers Amputation Risk

May 22, 2009 4:35 am | News | Comments

MARIA CHENG AP Medical Writer LONDON (AP) — Doctors who gave diabetics a drug originally intended to lower patients' cholesterol found it reduced their risk of so-called minor amputation by 36 percent, a new analysis of research says.

FDA Approves Pancreatic Enzyme Replacement Product for Marketing in United States

May 7, 2009 7:13 am | News | Comments

The FDA announced today that it has approved Creon (pancrelipase), a pancreatic enzyme replacement product designed to help patients with cystic fibrosis and others with exocrine pancreatic insufficiency (EPI) digest and absorb nutrients from foods.

Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement

February 2, 2009 4:41 am | News | Comments

Par Pharmaceutical Companies, Inc. has learned that the Federal Trade Commission and the California Attorney General filed a lawsuit against Par in the U.S. District Court for the District of Central California.

Advertisement

Depomed’s License Agreement With Solvay Pharmaceuticals Clears HSR Review

January 7, 2009 10:51 am | News | Comments

Depomed, Inc. has announced that the previously announced product license agreement under which

ANI Pharmaceuticals, Inc. Acquires State-of-the-Art Rx Facilities and Inks Long-Term Supply Agreement with Solvay Pharmaceuticals

May 9, 2007 5:33 am | News | Comments

ANI Pharmaceuticals has announced a major expansion of its Rx capabilities with the acquisition from Solvay Pharmaceuticals, Inc. of two manufacturing facilities located in Baudette, MN. The plants add 173,000 sq. ft.

FDA Accepts ACEON Supplemental New Drug Application for Filing (2710)

March 11, 2005 4:35 am | Product Releases | Comments

MARIETTA, Ga. and PALO ALTO, Calif., Feb. 15 -- Solvay Pharmaceuticals, Inc. and CV Therapeutics, Inc. announced today that the U.S.

FDA Accepts ACEON Supplemental New Drug Application for Filing

February 17, 2005 6:24 am | Product Releases | Comments

MARIETTA, Ga. and PALO ALTO, Calif., Feb. 15 -- Solvay Pharmaceuticals, Inc. and CV Therapeutics, Inc. announced today that the U.S.

Bristol-Myers Squibb and Solvay Agree to Develop Obesity Compound

May 17, 2004 7:18 am | Product Releases | Comments

NEW YORK, NY (May 17, 2004) – Bristol-Myers Squibb Co. and Solvay Pharmaceuticals have agreed to jointly develop and commercialize Solvay compound SLV319, which is currently in Phase I development with potential foruse in treating obesity and other metabolic disorders, the companies announced.

Wyeth, Solvay to Co-Develop Product Candidates and Co-Promote

April 5, 2004 9:21 am | Product Releases | Comments

MADISON, NJ (April 5, 2004) – Wyeth Pharmaceuticals said it has entered into an agreement with Solvay Pharmaceuticals to co-develop and co-commercialize four neuroscience compounds, most notably, bifeprunox – a late-stage compound in Phase 3 development for schizophrenia and other possible uses.

Advertisement
X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading